Phaseline

Companies › XingImaging

XingImaging: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[¹⁸F]MK-0947
alpha-synuclein (ASYN) PET imaging agent
SNCAPhase 1Parkinsons Disease (PD)Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07880379[¹⁸F]MK-0947Phase 1Parkinsons Disease (PD)NeurologySep 2027

Targets

SNCA (1)

Companies with the same targets

Teva Branded Pharmaceutical Products R&D AC Immune Regeneron Pharmaceuticals Roche

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.